Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Biological warfare Stories

2011-10-12 14:33:00

OREM, Utah, Oct. 12, 2011 /PRNewswire/ -- When letters containing anthrax spores were mailed to two U.S. Senators in October 2001, the Hart Senate Office Building and two postal facilities were closed for more than a year. Remediation costs ran into the hundreds of millions of dollars. STERIPLEX Ultra kills anthrax spores in 30 minutes. Contaminated buildings may be reoccupied in hours. Unlike other sporicides, STERIPLEX Ultra is non-corrosive, non-fuming, non-toxic to inhale and not a...

2011-09-29 05:30:00

WASHINGTON, Sept. 29, 2011 /PRNewswire-USNewswire/ -- October 2011 marks the 10 year anniversary of the anthrax attacks in the United States. The following is a statement from Jeff Levi, Ph.D., Executive Director of the Trust for America's Health (TFAH): (Logo: http://photos.prnewswire.com/prnh/20100204/TFAHLOGO) "All of us at the Trust for America's Health want to take this anniversary to remember those we lost and their loved ones and to commemorate the public health community and...

2011-09-09 08:00:00

ANNAPOLIS, Md., Sept. 9, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP) announced today that it has achieved significant progress in the development of its second generation anthrax vaccine, SparVax(TM). In addition to completing initial technology transfer at the 100 liter scale and demonstrating 36 month stability, the Company announced today that it has now completed a 1,500 liter engineering production run for SparVax(TM). As a result, PharmAthene has shown it is able to...

2011-09-09 08:12:00

Recommendations Offered on Future Direction BALTIMORE, Sept. 9, 2011 /PRNewswire-USNewswire/ -- The Center for Biosecurity of UPMC released online ahead of print a new publication, A Crossroads in Biosecurity: Steps to Strengthen U.S. Preparedness, which takes stock of progress since 2001 and makes recommendations for change that would help build resilience and preparedness against biological threats. "Many important government and private sector programs were born in response to the...

2011-09-08 09:00:00

PINE BROOK, N.J., Sept. 8, 2011 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing biodefense countermeasures, announced today that it has been awarded the first U.S. Government contract to develop an anti-toxin for pre- and post-exposure prophylaxis (PEP) use via intramuscular injection (IM). The five year contract, totaling up to $68.9 million, will support multiple animal efficacy studies as well as human safety studies to further demonstrate...

2011-08-10 15:12:00

ANNAPOLIS, Md., Aug. 10, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operating results for the second quarter ended June 30, 2011. For the second quarter of 2011 PharmAthene recognized revenue of $6.4 million compared to $4.8 million in the same period of 2010. Revenues for the most recent quarter consisted of contract funding from the U.S. government...

2011-07-25 23:40:05

Around the globe, many nations are realizing that the potential for bioterrorism isn't just about the U.S., officials say. And because an intentional introduction of bacteria, a virus or a toxin could happen anywhere, the World Organization for Animal Health is issuing a paper aimed at prevention. "Any emerging country that is beginning to think about maintaining international trade needs to be aware of the potential for bioterrorism," said Dr. Neville Clarke, special assistant to the Texas...

2011-07-12 06:00:00

ANNAPOLIS, Md., July 12, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP) announced today that it has achieved an important program milestone in its recombinant protective antigen (rPA) anthrax vaccine program and demonstrated 36 month stability of its rPA drug product candidate previously produced at Avecia Biologics Laboratories in the United Kingdom. The stability data were prepared utilizing a variety of analytical methods and a well characterized mouse challenge potency assay....

2011-06-27 09:00:00

ANNAPOLIS, Md., June 27, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP) announced today that it has achieved an important technical milestone in its recombinant protective antigen (rPA) anthrax vaccine program. PharmAthene has successfully completed initial technology transfer of its manufacturing process for the bulk drug substance of its vaccine candidate, SparVax(TM), at the 100 liter scale to a US-based manufacturing facility at Diosynth RTP. Activities to scale-up...

2011-06-14 06:50:00

MCLEAN, Va., June 14, 2011 /PRNewswire/ -- Science Applications International Corporation (SAIC) [NYSE: SAI] today announced it has been awarded a delivery order to support the U.S. Air Force (AF) Deputy Chief of Staff for Operations, Plans and Requirements, Strategic Plans and Policy Division (AF/A5XP) by providing professional and information technology (IT) services in support of AF national security initiatives. The delivery order has a five-year period of performance and a total...